AI for Smarter Healthcare
Keya Medical Raises Over $20 Million in Series B+ Financing Round
Keya Medical was founded in 2016 to harness artificial intelligence to develop innovative diagnostic products that improve healthcare. Collaborating with leading healthcare systems in North America, Europe, and Asia, Keya Medical provides AI-enabled technology that helps medical professionals deliver better care.
DEEPVESSEL FFR* uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary CT angiogram scans. The software reduces unnecessary invasive testing to lower costs and complications.
*CE Marked, National Medical Products Administration (NMPA) Approved. Not for sale in the United States.
DEEPVESSEL FFR Approved for Clinical Use in China
Who do we work with
Keya Medical is committed to developing medical imaging AI solutions in collaboration with healthcare providers. Since 2016, we have worked with more than 200 hospitals around the world.
Keya Medical is continuing to develop new solutions to improve cardiovascular disease diagnosis and treatment. We invite payers to continue the conversation on how our solutions can create savings.
Start a collaboration with Keya Medical
On Sept. 18, Keya Medical was recognized as the winner of of China’s Most Promising Company award because of its leading R&D team and innovative cardiovascular product line.
On Sept. 10, Keya Medical was invited to deliver an academic lecture to more than 130 imaging departments in honor of the newly established Northern Jiangsu People’s Hospital Medical Imaging Alliance.
During QICC 2020, Dr. Xinyang Hu delivered a special lecture on the clinical significance of non-invasive CT-FFR.